Literature DB >> 25585656

Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient.

Arnulf Ferlitsch1, Simona Bota1, Rafael Paternostro1, Thomas Reiberger1, Mattias Mandorfer1, Birgit Heinisch1, Petra Salzl1, Remy Schwarzer1, Wolfgang Sieghart1, Markus Peck-Radosavljevic1, Monika Ferlitsch1.   

Abstract

BACKGROUND & AIMS: Despite the important clinical value of hepatic venous pressure gradient (HVPG) and its increasing use, no specific balloon occlusion catheters have been designed to cannulate liver veins. The aim of the study was to evaluate the clinical applicability of a novel balloon (NC) occlusion catheter specifically designed for HVPG measurement.
METHODS: Comparison of a new CE-certified 7 French balloon occlusion catheter with a 150° angled tip and radiopaque markers (NC, Pejcl Medizintechnik, Austria), to a commonly used straight balloon catheter (SC; Boston Scientific, USA). Successful liver vein cannulation rate, need for extra equipment and total fluoroscopy time were recorded. Experts (>200) and novices (<20) in HVPG measurements were evaluated separately.
RESULTS: 566 HVPG measurements taken by 11 investigators (five experts and six novices) were analysed. Overall, HVPG could be successfully measured in 98.7% of cases. The rate of successful liver vein cannulation at first attempt was significantly higher among experts when compared to novices (87.3% vs 67.3%, P < 0.001). Moreover, the rate of successful liver vein cannulation without need for any additional equipment was higher when using the NC, both among experts (NC:91.9% vs SC:80.6%, P = 0.03) and novices (NC:73.3% vs SC:50.7%, P = 0.001). The mean fluoroscopy time needed to cannulate the hepatic vein was significantly shorter in experts as compared to novices [2.37(0.10-26) vs 5.2(0.6-30.2] min, P < 0.0001), but not significantly different between catheters.
CONCLUSIONS: Both novices and experts achieve higher liver vein cannulation rates using the new specifically designed catheter. The use of the novel catheter might increase rates of successful liver vein cannulation and reduce the need for additional equipment, especially in novices.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HVPG; catheter; cirrhosis; portal hypertension; variceal bleeding

Mesh:

Year:  2015        PMID: 25585656     DOI: 10.1111/liv.12783

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  19 in total

1.  EUS-guided portal pressure measurement using a digital pressure wire with real-time remote display: a novel, minimally invasive technique for direct measurement in an animal model.

Authors:  Allison R Schulman; Christopher C Thompson; Marvin Ryou
Journal:  Gastrointest Endosc       Date:  2015-12-10       Impact factor: 9.427

2.  Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis.

Authors:  Rafael Paternostro; Doris Wagner; Thomas Reiberger; Mattias Mandorfer; Remy Schwarzer; Monika Ferlitsch; Michael Trauner; Markus Peck-Radosavljevic; Arnulf Ferlitsch
Journal:  Wien Klin Wochenschr       Date:  2016-11-25       Impact factor: 1.704

3.  Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension.

Authors:  M Mandorfer; B Scheiner; A F Stättermayer; P Schwabl; R Paternostro; D Bauer; B Schaefer; H Zoller; M Peck-Radosavljevic; M Trauner; T Reiberger; P Ferenci; A Ferlitsch
Journal:  Aliment Pharmacol Ther       Date:  2018-06-29       Impact factor: 8.171

4.  The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease.

Authors:  Bernhard Scheiner; Patrick G Northup; Anselm B Gruber; Georg Semmler; Gerda Leitner; Peter Quehenberger; Johannes Thaler; Cihan Ay; Michael Trauner; Thomas Reiberger; Ton Lisman; Mattias Mandorfer
Journal:  Liver Int       Date:  2020-03-04       Impact factor: 5.828

5.  Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.

Authors:  Benedikt Simbrunner; Rodrig Marculescu; Bernhard Scheiner; Philipp Schwabl; Theresa Bucsics; Alexander Stadlmann; David J M Bauer; Rafael Paternostro; Ernst Eigenbauer; Matthias Pinter; Albert Friedrich Stättermayer; Michael Trauner; Mattias Mandorfer; Thomas Reiberger
Journal:  Liver Int       Date:  2020-05-18       Impact factor: 5.828

6.  Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension.

Authors:  Rafael Paternostro; Birgit B Heinisch; Thomas Reiberger; Mattias Mandorfer; Remy Schwarzer; Berit Seeland; Michael Trauner; Markus Peck-Radosavljevic; Arnulf Ferlitsch
Journal:  Liver Int       Date:  2018-02-20       Impact factor: 5.828

7.  Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.

Authors:  Bernhard Scheiner; Gregor Ulbrich; Mattias Mandorfer; Thomas Reiberger; Christian Müller; Fredrik Waneck; Michael Trauner; Claus Kölblinger; Arnulf Ferlitsch; Wolfgang Sieghart; Markus Peck-Radosavljevic; Matthias Pinter
Journal:  United European Gastroenterol J       Date:  2019-03-21       Impact factor: 4.623

8.  Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).

Authors:  Thomas Reiberger; Andreas Püspök; Maria Schoder; Franziska Baumann-Durchschein; Theresa Bucsics; Christian Datz; Werner Dolak; Arnulf Ferlitsch; Armin Finkenstedt; Ivo Graziadei; Stephanie Hametner; Franz Karnel; Elisabeth Krones; Andreas Maieron; Mattias Mandorfer; Markus Peck-Radosavljevic; Florian Rainer; Philipp Schwabl; Vanessa Stadlbauer; Rudolf Stauber; Herbert Tilg; Michael Trauner; Heinz Zoller; Rainer Schöfl; Peter Fickert
Journal:  Wien Klin Wochenschr       Date:  2017-10-23       Impact factor: 1.704

9.  Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.

Authors:  Bernhard Scheiner; Lisa Steininger; Georg Semmler; Lukas W Unger; Philipp Schwabl; Theresa Bucsics; Rafael Paternostro; Arnulf Ferlitsch; Michael Trauner; Thomas Reiberger; Mattias Mandorfer
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

10.  Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.

Authors:  Bernhard Scheiner; Albert F Stättermayer; Philipp Schwabl; Theresa Bucsics; Rafael Paternostro; David Bauer; Benedikt Simbrunner; Ralf Schmidt; Rodrig Marculescu; Arnulf Ferlitsch; Markus Peck-Radosavljevic; Mathias Pinter; Michael Trauner; Thomas Reiberger; Peter Ferenci; Mattias Mandorfer
Journal:  Liver Int       Date:  2019-12-03       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.